selectION Announces Positive Results from Phase 1b Clinical

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear or

Related Keywords

Germany , Martinsried , Bayern , Munich , San Diego , California , United States , Ludger Wess Ines Regina Buth , Andreas Klostermann , Steve Zaniboni , Lion Inc , Chief Scientific Officer , Antonius Schuh , Global Source , Ludger Wess , Business ,